A study to determine which treatment is more effective between a new procedure using CT imaging and a conventional procedure in patients with atrial fibrillation

Computed Tomogram Myocardial thickness map guided pulmOnary vein iSolaTion vs. Empirical pulmonary vein isolation in pulse-field ablation for paroxysmal atrial fibrillation (UTMOST AF III)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011584

Enrollment

298

Registered

2026-02-06

Start date

2026-02-27

Completion date

Unknown

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : 1) CT myocardial thickness map guided PV isolation Group 1. Conventional pulmonary vein isolation is performed using a pulsed field ablation catheter. 2. A myocardial thickness map

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 19 years or older who are indicated for catheter ablation for paroxysmal atrial fibrillation. 2. Patients with paroxysmal atrial fibrillation who have experienced recurrence despite antiarrhythmic drug therapy or in whom antiarrhythmic drugs are contraindicated or not tolerated.

Exclusion criteria

Exclusion criteria: 1. Left atrial anteroposterior diameter = 50 mm. 2. Patients with persistent or permanent atrial fibrillation. 3. Patients with severe renal impairment (estimated glomerular filtration rate [estimated glomerular filtration rate] by Chronic Kidney Disease Epidemiology Collaboration < 30 mL/min/1.73 m²) or those for whom contrast-enhanced CT imaging is not feasible. 4. Patients with a history of surgical or catheter-based atrial fibrillation ablation. 5. Patients with active internal bleeding. 6. Contraindications to anticoagulation therapy (antithrombotic treatment for stroke prevention). 7. Patients with moderate to severe mitral stenosis (mitral valve area [MVA] by pressure half-time [PHT] or 2D echocardiography < 2.0 cm²) or a history of mechanical heart valve replacement. 8. Patients with clinically significant serious comorbidities. 9. Patients with an expected life expectancy of less than 1 year. 10. Patients with drug or alcohol abuse. 11. Patients unable to read or understand the informed consent form (e.g., illiteracy or foreign nationals with language barriers). 12. Patients deemed unsuitable for participation in the clinical trial based on the investigator’s judgment.

Design outcomes

Primary

Measure	Time frame
Clinical recurrence rate: incidence of atrial fibrillation or atrial tachycardia lasting =30 seconds occurring more than 3 months after the procedure	—

Secondary

Measure	Time frame
A comprehensive assessment of procedural safety, procedural parameters, medication-related adverse events, clinical course, and major cardiovascular events	—

Countries

Korea, Republic of

Contacts

Public Contacthui-nam Park

Yonsei University Health System, Severance Hospital

hnpak@yuhs.ac+82-2-2228-8528

Outcome results